RESEARCH AND PRODUCT DEVELOPMENT
Biotie’s drug development portfolio covers a range of product candidates at various stages of clinical and pre-clinical development. The portfolio includes small molecules and a novel biological compound. These drug candidates address signifi cant areas of unmet clinical need and thus command substantial potential markets in the areas of central nervous system (CNS) disorders and infl ammatory diseases. Biotie's scientists have highly competitive capabilities to identify, optimize and develop novel, potent, drug-like small molecule compounds and biological entities addressing a variety of molecular targets. These efforts have proven successful in providing a steady fl ow of new drug candidates in the past and it remains our goal to deliver a stream of patent protected clinical development candidates for further development in the future.